These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 9468586)

  • 21. [Treatment of malignant pleural mesothelioma--present status and future view].
    Yano T; Morodomi Y; Ito K; Miura N; Takenaka T; Kawano D; Shoji F; Maehara Y
    Fukuoka Igaku Zasshi; 2008 Apr; 99(4):74-9. PubMed ID: 18646592
    [No Abstract]   [Full Text] [Related]  

  • 22. Mesothelioma: path to multimodality treatment.
    Su S
    Semin Thorac Cardiovasc Surg; 2009; 21(2):125-31. PubMed ID: 19822284
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunotherapy of HIV-infected patients with intermittent interleukin-2: effects of cycle frequency and cycle duration on degree of CD4(+) T-lymphocyte expansion.
    Miller KD; Spooner K; Herpin BR; Rock-Kress D; Metcalf JA; Davey RT; Falloon J; Kovacs JA; Polis MA; Walker RE; Masur H; Lane HC
    Clin Immunol; 2001 Apr; 99(1):30-42. PubMed ID: 11286539
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low-dose prolonged intermittent interleukin-2 adjuvant therapy: results of a randomized trial among human immunodeficiency virus-positive patients with advanced immune impairment.
    Marchetti G; Meroni L; Varchetta S; Terzieva V; Bandera A; Manganaro D; Molteni C; Trabattoni D; Fossati S; Clerici M; Galli M; Moroni M; Franzetti F; Gori A
    J Infect Dis; 2002 Sep; 186(5):606-16. PubMed ID: 12195347
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overview of interleukin-2 inhalation therapy.
    Huland E; Heinzer H; Huland H; Yung R
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S104-12. PubMed ID: 10685669
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Time-dependent cytokine deviation toward the Th2 side in Japanese multiple sclerosis patients with interferon beta-1b.
    Ochi H; Feng-Jun M; Osoegawa M; Minohara M; Murai H; Taniwaki T; Kira J
    J Neurol Sci; 2004 Jul; 222(1-2):65-73. PubMed ID: 15240198
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Flowcytometric immunophenotyping of peripheral-blood leukocytes in relation to immunopathology and cellular proliferation of pleural mesothelioma.
    ElGendy AM; Abbas Helmy WH; Ezz-ElArab A
    Egypt J Immunol; 2006; 13(1):87-98. PubMed ID: 17974153
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunophenotypic profile of peripheral blood eosinophils in acute graft-vs.-host disease.
    Rumi C; Rutella S; Bonini S; Bonini S; Lambiase A; Sica S; Puggioni P; Salutari P; Etuk B; Leone G
    Exp Hematol; 1998 Feb; 26(2):170-8. PubMed ID: 9472806
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Recent progress in treatment of malignant pleural mesothelioma].
    Mahé MA; Cellerin L; Michaud JL; Sagan C; Supiot S; Le Péchoux C
    Cancer Radiother; 2005 Nov; 9(6-7):362-5. PubMed ID: 16219479
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunotherapy-based treatment strategies for malignant mesothelioma.
    Schwarzenberger P; Byrne P; Kolls JK
    Curr Opin Mol Ther; 1999 Feb; 1(1):104-11. PubMed ID: 11249674
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The pathology associated with therapeutic procedures in malignant mesothelioma.
    Attanoos RL; Gibbs AR
    Histopathology; 2004 Oct; 45(4):393-7. PubMed ID: 15469478
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Pleural mesothelioma. A case report].
    Della Vittoria Scarpati M; Parascandolo V; Santini M; Di Crescenzo VG; Di Lieto E; Vicidomini G
    Recenti Prog Med; 1999 Jun; 90(6):327-30. PubMed ID: 10399472
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interruption of antiretroviral therapy blunts but does not abrogate CD4 T-cell responses to interleukin-2 administration in HIV infected patients.
    Keh CE; Shen JM; Hahn B; Hallahan CW; Rehm CA; Thaker V; Wynne SM; Davey RT; Lane HC; Sereti I
    AIDS; 2006 Feb; 20(3):361-9. PubMed ID: 16439869
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hyperthermia and mafosfamide in a human-derived malignant pleural mesothelioma cell line.
    Ehlers EM; Kühnel W; Wiedemann GJ
    J Cancer Res Clin Oncol; 2002 Feb; 128(2):65-72. PubMed ID: 11862475
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: persistent transgene expression despite antibody generation.
    Mukherjee S; Haenel T; Himbeck R; Scott B; Ramshaw I; Lake RA; Harnett G; Phillips P; Morey S; Smith D; Davidson JA; Musk AW; Robinson B
    Cancer Gene Ther; 2000 May; 7(5):663-70. PubMed ID: 10830713
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Addition of histamine to interleukin 2 treatment augments type 1 T-cell responses in patients with melanoma in vivo: immunologic results from a randomized clinical trial of interleukin 2 with or without histamine (MP 104).
    Asemissen AM; Scheibenbogen C; Letsch A; Hellstrand K; Thorén F; Gehlsen K; Schmittel A; Thiel E; Keilholz U
    Clin Cancer Res; 2005 Jan; 11(1):290-7. PubMed ID: 15671558
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Eosinophils and C4 predict clinical failure of combination immunotherapy with very low dose subcutaneous interleukin-2 and interferon in renal cell carcinoma patients.
    Moroni M; Porta C; De Amici M; Quaglini S; Cattabiani MA; Buzio C
    Haematologica; 2000 Mar; 85(3):298-303. PubMed ID: 10702820
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of interleukin-8 reduces human malignant pleural mesothelioma propagation in nude mouse model.
    Galffy G; Mohammed KA; Nasreen N; Ward MJ; Antony VB
    Oncol Res; 1999; 11(4):187-94. PubMed ID: 10566617
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prolonged survival after talc poudrage for malignant pleural mesothelioma: case series.
    Aelony Y; Yao JF
    Respirology; 2005 Nov; 10(5):649-55. PubMed ID: 16268920
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase II study of intrapleural immunochemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy, and long-term subcutaneous IL-2 in stage II-III malignant pleural mesothelioma.
    Rusch VW
    Eur J Cardiothorac Surg; 2007 Mar; 31(3):534-5. PubMed ID: 17267238
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.